SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Compass Pathways Expects to Complete COMP360 FDA Filing Within Two Weeks

Compass Pathways expects to complete its New Drug Application for its depression treatment within two weeks. CEO Nath sees a potential commercial launch in the first half of 2027.

CMPS
SquawkNews Desk

Related stories

Meta Set to Raise $15 Billion From US Dollar Bond Sale M impact | EQUITY | Nov 03, 2026, 07:32 PM UTC Invesco Reports Third-Quarter Revenue of $1.87 Billion Invesco reported revenue of $1.87 billion, up 14.2% year over year. Net income attributable to the company declined 2.3% to $294.5 million, while diluted EPS fell to $0.65 from $0. M impact | EQUITY | Nov 03, 2026, 07:31 PM UTC GPODS Reports $107,175 Third-Quarter Net Loss GPODS reported a net loss of $107,175 for the quarter ended September 30, 2026, narrowed from $123,515 a year earlier. Diluted EPS was $(0.01) in both periods, with no product sale M impact | EQUITY | Nov 03, 2026, 07:31 PM UTC US session market picture: S&P 500 +0.44%, Nasdaq 100 +0.78%; EUR/USD +0.05%, WTI -0.47%, WBD leads volume US session market picture. US index futures: S and P futures is up 0.44 percent, Nasdaq futures is up 0.78 percent, Dow futures is down 0.33 percent and Russell futures is up 0.58 M impact | EQUITY | Nov 03, 2026, 07:30 PM UTC Nasdaq Composite Rises More Than 1% in Afternoon Trading The index is looking to break a three-session losing streak as investors shift attention from earnings to the U.S. midterm elections. M impact | EQUITY | Nov 03, 2026, 07:28 PM UTC US Restrictions Complicate SK Hynix’s New York Chip Plans US officials have held up approval for chipmaking equipment SK Hynix needs to expand production in China, complicating plans for new memory-chip plants in New York, people familiar L impact | EQUITY | Nov 03, 2026, 07:25 PM UTC